High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer

Abstract

Purpose Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer. Methods 225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS). Results High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for progression-free survival. Conclusion Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future.

A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity

“…However, the role of RIG-I in cancer is not without controversy. RIG-I expression is downregulated and correlates with prolonged survival in HCC, but high RIG-I expression predicts poor clinical outcome for endometrial cancer [ 41 , 42 ]. Here, we show circKEAP1 triggers an immune defense response by binding to RIG-I in OS cells.…”

A label free chemoproteomic-based platform to disclose cannabidiol molecular mechanism of action on chronic myelogenous leukemia cancer cells

“…This is an element of high novelty since the role of EFTUD2 has been underestimated in the field of cancer research in comparison to others small nuclear ribonucleoprotein such as U2AF1 and SF3B1. Indeed, up to now, only four papers have been published describing the involvement of EFTUD2 in the colitis-associated tumorigenesis [ 30 ], in the endometrial cancer [ 31 ] and in the HCC [ 32 , 33 ] .…”

RIG-I Promotes Tumorigenesis and Confers Radioresistance of Esophageal Squamous Cell Carcinoma by Regulating DUSP6

“…In addition, ESCC cell migration and invasion can lead to metastasis [ 1 , 3 ]. RIG-I plays an important regulatory role in the development of a variety of tumors [ 20 , 21 , 22 , 23 , 24 , 26 ]; its expression is upregulated in ovarian [ 22 ], colorectal [ 23 ], and endometrial cancers [ 24 ]. This study, for the first time, confirmed the carcinogenic effect of RIG-I in ESCC.…”

“…Although the regulatory role in tumors has been demonstrated, the low expression of RIG-I in melanoma and colon cancer is associated with a poor prognosis [ 20 , 21 ]. RIG-I is overexpressed in ovarian, colorectal, and endometrial cancers; it plays an essential role in proliferation, apoptosis, and immune escape [ 22 , 23 , 24 ]. Therefore, RIG-I is a potential target for cancer treatment.…”